Ian McLeod's most recent trade in Anika Therapeutics Inc. was a trade of 17,663 Premium Priced Stock Appreciation Rights done . Disclosure was reported to the exchange on March 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 17,663 | 17,663 | - | - | Premium Priced Stock Appreciation Rights | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 13,097 | 13,097 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2026 | 11,194 | 11,194 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 3,774 | 7,550 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 3,774 | 22,518 (0%) | 0% | - | Common Stock | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 2,658 | 2,659 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 2,658 | 24,888 (0%) | 0% | - | Common Stock | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.20 per share. | 14 Mar 2026 | 1,449 | 22,230 (0%) | 0% | 14.2 | 20,576 | Common Stock |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2026 | 1,161 | 23,679 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc | Ian McLeod | SVP, CAO & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.20 per share. | 14 Mar 2026 | 781 | 24,107 (0%) | 0% | 14.2 | 11,090 | Common Stock |
| Anika Therapeutics Inc | Ian James Winward McLeod | SVP, CAO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 2,197 | 19,383 (0%) | 0% | - | Common Stock | |
| Anika Therapeutics Inc | Ian James Winward McLeod | SVP, CAO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 2,197 | 0 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc | Ian James Winward McLeod | SVP, CAO & Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.96 per share. | 09 Mar 2026 | 639 | 18,744 (0%) | 0% | 15.0 | 9,559 | Common Stock |